Environmental Research 2009-01-01

Cancer incidence among pesticide applicators exposed to butylate in the Agricultural Health Study (AHS)

Shannon M. Lynch, Rajeev Mahajan, Laura E. Beane Freeman, Jane A. Hoppin, Michael C.R. Alavanja, Shannon M. Lynch, Rajeev Mahajan, Laura E. Beane Freeman, Jane A. Hoppin, Michael C.R. Alavanja

文献索引：Environ. Res. 109(7) , 860-8, (2009)

全文：HTML全文

摘要

Although limited, epidemiologic studies suggest possible associations between butylate use and cancer risk, specifically prostate cancer and non-Hodgkin lymphoma (NHL). We examined butylate use and cancer risk more broadly in the AHS, a cohort of licensed pesticide applicators in Iowa and North Carolina. Pesticide use information was collected using self-administered questionnaires. Poisson regression was used to calculate rate ratios (RR) and 95% confidence intervals (CI). Two exposure metrics were used: lifetime exposure days (LD) and intensity-weighted lifetime exposure days (IWLD). We used two referent groups: unexposed to butylate and the lowest butylate usage category. This analysis included 19,655 applicators with complete butylate use information; 5297 applicators were exposed to butylate, making this the largest study of butylate to date. The mean follow-up time since enrollment was 9 years. Prostate cancer risk was significantly elevated among applicators in the highest LD category in both referent groups (low-exposed referent: RR LD=2.09, 95% CI=1.27–3.44). We observed a significantly elevated joint effect of prostate cancer family history and high butylate usage across both exposure metrics and both referent groups (low-exposed referent: RR LD=2.00, 95% CI=1.07–3.74), and a non-significant, elevated interaction between butylate use and prostate cancer family history, similar to a previous AHS finding. Statistically significant increased risks and exposure–response trends were seen for all lymphohematopoietic cancers (AL) and NHL for both exposure metrics and referent groups (low-exposed referent: AL:RR LD=2.27, 95% CI=1.18–4.37; NHL: RR LD=3.44, 95% CI=1.29–9.21). Our analysis did not find meaningful associations for other cancers analyzed. Further study is warranted for AL, NHL and prostate cancers.